flow trial semaglutide renal outcomes 2024 in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical Long-term kidney outcomes of semaglutide

2020 Apr;35(4):54456

Cohen holds a BSc (Hons) in microbiology and biochemistry from University of Cape Town, South Africa, and has a Ph.D., summa cum laude, from the Curie Institute of Cancer Research in Paris and the University of Paris V

A., Mocan, A., Echeverra, J., Pop, R

Renal cortical tubules express the enzyme myo-inositol oxygenase

Patients in the study were randomized in a 1:1:1:1 ratio to receive retatrutide (4 mg, 9 mg, 12 mg) or placebo over a period of 80 weeks

Research protocol design for combination studies should include staggered dosing schedules, lowest effective peptide doses, and behavioral monitoring for signs of receptor oversaturation